Thrombophilia in pregnancy

Area of Science:

• Hematology
• Obstetrics
• Genetics

Background:

• Thrombophilia is a predisposition to thrombosis, encompassing heritable and acquired hemostasis abnormalities.
• Known defects include mutations in natural anticoagulants (antithrombin, protein C, protein S) and clotting factors (prothrombin, factor V), as well as antiphospholipids.
• Women with thrombophilic defects face elevated risks of pregnancy-associated thromboembolism, pre-eclampsia, and fetal loss.

Purpose of the Study:

• To evaluate the implications of thrombophilic defects in pregnancy.
• To determine the recommended approach for thrombophilia screening in pregnant women.
• To identify specific thrombophilic defects warranting screening for risk assessment and management planning.

Main Methods:

• Review of existing literature on thrombophilia and pregnancy complications.
• Analysis of risks associated with specific thrombophilic defects during gestation.
• Evaluation of current screening recommendations for antenatal care.

Main Results:

• Routine screening for thrombophilia in all pregnant women is not advised.
• Certain defects, like type 1 antithrombin deficiency and antiphospholipids, confer a high risk of recurrent thrombosis and pregnancy complications.
• Selected women with a history of venous thromboembolism or recurrent fetal loss may benefit from targeted screening.

Conclusions:

• Thrombophilia screening should be individualized based on patient history.
• Screening selected high-risk women allows for proactive pregnancy management planning.
• Further research may refine risk stratification and management strategies for thrombophilic defects in pregnancy.